447 related articles for article (PubMed ID: 27372043)
1. Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients.
Gu J; Fan YQ; Han ZH; Fan L; Bian L; Zhang HL; Xu ZJ; Yin ZF; Xie YS; Zhang JF; Wang CQ
Int J Cardiol; 2016 Oct; 220():56-60. PubMed ID: 27372043
[TBL] [Abstract][Full Text] [Related]
2. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study.
Gu J; Fan YQ; Bian L; Zhang HL; Xu ZJ; Zhang Y; Chen QZ; Yin ZF; Xie YS; Wang CQ
Eur J Prev Cardiol; 2016 Sep; 23(13):1421-8. PubMed ID: 26915580
[TBL] [Abstract][Full Text] [Related]
3. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
Kurrelmeyer KM; Ashton Y; Xu J; Nagueh SF; Torre-Amione G; Deswal A
J Card Fail; 2014 Aug; 20(8):560-8. PubMed ID: 24905296
[TBL] [Abstract][Full Text] [Related]
4. Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Pan JA; Lin H; Wang CQ; Zhang JF; Gu J
Heart Vessels; 2020 Oct; 35(10):1446-1453. PubMed ID: 32430700
[TBL] [Abstract][Full Text] [Related]
5. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
Kosmala W; Przewlocka-Kosmala M; Marwick TH
JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
[TBL] [Abstract][Full Text] [Related]
6. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
[TBL] [Abstract][Full Text] [Related]
7. Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension.
Gu J; Yin ZF; Zhang JF; Wang CQ
Int J Cardiol; 2020 May; 306():140-145. PubMed ID: 31711850
[TBL] [Abstract][Full Text] [Related]
8. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Shah AM; Shah SJ; Anand IS; Sweitzer NK; O'Meara E; Heitner JF; Sopko G; Li G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD;
Circ Heart Fail; 2014 Jan; 7(1):104-15. PubMed ID: 24249049
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction.
Melenovsky V; Borlaug BA; Rosen B; Hay I; Ferruci L; Morell CH; Lakatta EG; Najjar SS; Kass DA
J Am Coll Cardiol; 2007 Jan; 49(2):198-207. PubMed ID: 17222731
[TBL] [Abstract][Full Text] [Related]
10. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
11. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of systolic and diastolic properties of hypertensive heart failure using speckle-tracking echocardiography with high volume rates.
Minatoguchi S; Kawasaki M; Tanaka R; Yoshizane T; Ono K; Saeki M; Nagaya M; Sato H; Nishigaki K; Noda T; Zile MR; Minatoguchi S
Heart Vessels; 2017 Oct; 32(10):1202-1213. PubMed ID: 28638961
[TBL] [Abstract][Full Text] [Related]
13. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
Edelmann F; Gelbrich G; Duvinage A; Stahrenberg R; Behrens A; Prettin C; Kraigher-Krainer E; Schmidt AG; Düngen HD; Kamke W; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
Int J Cardiol; 2013 Nov; 169(6):408-17. PubMed ID: 24182675
[TBL] [Abstract][Full Text] [Related]
14. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.
Gupta A; Schiros CG; Gaddam KK; Aban I; Denney TS; Lloyd SG; Oparil S; Dell'Italia LJ; Calhoun DA; Gupta H
J Hum Hypertens; 2015 Apr; 29(4):241-6. PubMed ID: 25231508
[TBL] [Abstract][Full Text] [Related]
15. Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.
Valero-Munoz M; Li S; Wilson RM; Boldbaatar B; Iglarz M; Sam F
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 27810862
[TBL] [Abstract][Full Text] [Related]
16. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
[TBL] [Abstract][Full Text] [Related]
17. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
[TBL] [Abstract][Full Text] [Related]
18. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN
Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
